![](https://investorshub.advfn.com/uicon/392331.png?cb=1644257229)
Wednesday, March 04, 2020 1:23:16 PM
PAUL M. MICHAELS
For the past two decades, Mr. Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few.
Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market in addition to other corporate responsibilities that included overall evaluation of corporate asset values. Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
Paul began his career as Co-Founder, Executive Vice President and Board Member of Global Capital Group, a publicly traded corporate finance firm on Wall Street where he structured, financed and advised transactions in multiple spaces utilizing a variety of financial vehicles including private placements and Initial Public Offerings.
He received his Bachelor’s degree from Tulane University and completed an HBX program from Harvard.
https://www.nobelpharma.co.jp/en/index.html
https://sunmedadvisors.com/
All of my posts are my opinion only and are not meant to be investment advice.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM